It's odd that treatment with olaparib didn't have an effect...

It's odd that treatment with olaparib didn't have an effect here, given that it has been shown in other trials to cross the blood brain barrier in humans.

e.g. a phase 1 trial (OPARATIC, published late last year) showed that the antibody could be recovered from resected human tumours

Preclinical mouse work did not demonstrate that the drug could cross the barrier and yet it seems to be able to in man - there is clearly a major problem with the animal model or the assay used. I wonder how Patrys have addressed this.

None of this answers the question of why they thought it was important to combine their drug with olaparib in the first place - it looks like a fishing expedition to me.